The risk of interstitial lung disease during biological treatment in Japanese patients with psoriasis
- 1 May 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 45 (7), 853-858
- https://doi.org/10.1111/ced.14259
Abstract
Background As biological agents have been widely used for the treatment of psoriasis, increasing numbers of interstitial lung disease (ILD) associated with biologics are reported. Many were associated with tumor necrosis factor α (TNFα) inhibitors, moreover, cases even associated with other family biologics were reported in Japan. Aim To analyze the background factors of patients who developed ILD, and to discuss a better management of biological treatment. Method We reviewed 246 psoriasis patients who were treated with biological agents in our department to find pulmonary adverse events. Patients who developed ILD were extracted to analyze background factors; clinical types of psoriasis, duration to the onset of ILD, pre‐existed ILD, smoking habits, and combined drugs. Results Pulmonary adverse events (AE) were seen in 22 cases, of which, 11 cases were diagnosed as drug‐induced interstitial lung disease (ILD). The causative drug was mainly TNF‐α inhibitor, accounting for 8 cases (infliximab 6, adalimumab 2). There was one each in a case of ILD associated with secukinumab, ustekinumab, and ixekizumab, respectively. Notably, those 3 cases had a history of drug‐induced IP. Conclusion Patients who had a history of drug induced ILD seem to be very sensitive of developing another ILD induced by biologics, even by interleukin (IL)‐17 inhibitors. Thorough screenings of risk factors and evaluation for eligibility, as well as careful monitoring during treatment are the best solutions to avoid serious pulmonary AE. Early detection and precise diagnosis of pulmonary AE, especially the differentiation from infectious diseases is essential for managing biological treatment.Keywords
This publication has 22 references indexed in Scilit:
- Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2)British Journal of Dermatology, 2013
- Acute alveolitis following infliximab therapy for psoriasisAustralasian Journal of Dermatology, 2012
- Blocking IL-17A Promotes the Resolution of Pulmonary Inflammation and Fibrosis Via TGF-β1–Dependent and –Independent MechanismsThe Journal of Immunology, 2011
- Pulmonary Disorders Induced by Monoclonal Antibodies in Patients with Rheumatologic Autoimmune DiseasesThe American Journal of Medicine, 2011
- Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trialJournal of Dermatological Science, 2010
- Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled studyThe Journal of Dermatology, 2010
- Medikamenten-induzierte Alveolitis unterInfliximab-/Azathioprin-TherapiePneumologie, 2008
- Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2007
- Comparative Study of KL-6, Surfactant Protein-A, Surfactant Protein-D, and Monocyte Chemoattractant Protein-1 as Serum Markers for Interstitial Lung DiseasesAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Methotrexate-related pulmonary complications in rheumatoid arthritis.Annals Of The Rheumatic Diseases, 1994